Retrospective study for efficacy of ipilimumab and nivolumab in patients with high-grade neuroendocrine neoplasms
Latest Information Update: 01 Mar 2021
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Cervical cancer; Colon cancer; Gastric cancer; Intestinal cancer; Neuroendocrine tumours; Oesophageal cancer; Pancreatic cancer; Rectal cancer; Uterine cancer
- Focus Therapeutic Use
- 01 Mar 2021 New trial record
- 17 Jan 2021 Results presented at the 2021 Gastrointestinal Cancers Symposium